

DURECT CORP  
Form 8-K  
July 06, 2004

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## Form 8-K

---

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

July 6, 2004

Date of Report

(Date of earliest event reported)

---

## DURECT CORPORATION

(Exact name of Registrant as specified in its charter)

---

Delaware  
(State or other jurisdiction of  
incorporation or organization)

000-31615  
(Commission File Number)

94-3297098  
(I.R.S. Employer  
Identification No.)

10240 Bubb Road  
Cupertino, CA 95014

Edgar Filing: DURECT CORP - Form 8-K

(Address of principal executive offices) (Zip code)

(408) 777-1417

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

---

**Item 5. Other Events and Required FD Disclosure.**

On July 6, 2004, DURECT Corporation, a Delaware corporation (DURECT ), announced positive clinical results with its ORADUR<sup>®</sup> sustained release oral gel-cap technology.

A copy of DURECT's press release announcing positive clinical results with its ORADUR<sup>®</sup> sustained release oral gel-cap technology is attached as Exhibit 99.1 hereto and incorporated by reference herein.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**DURECT Corporation**

Date: July 6, 2004

By: /s/ James E. Brown

---

James E. Brown  
President and Chief Executive Officer

**DURECT CORPORATION**

**INDEX TO EXHIBITS**

<b><u>Exhibit Number</u></b>	<b><u>Description</u></b>
99.1	Press Release of DURECT Corporation dated July 6, 2004